Annovis Bio announces last patient last visit in Phase III study of buntanetap

Annovis Bio announced last patient last visit in the phase III study of its lead candidate buntanetap in patients with early Parkinson’s disease. Topline data results are expected in January 2024. “We are pleased to share the completion of our Parkinson’s study which marks a significant step forward in our ongoing mission to bring new therapies for those affected by this challenging neurodegenerative disease,” said Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis. “The study saw a substantial level of participation, with patients enrolling at a record pace.”